[{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biolab Sanus Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolab Sanus Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biolab Sanus Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biolab Sanus Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"NHS National Waiting Times Centre Board","sponsor":"British Heart Foundation | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"NHS National Waiting Times Centre Board","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"NHS National Waiting Times Centre Board \/ British Heart Foundation | Abbott Laboratories"},{"orgOrder":0,"company":"Darnitsa","sponsor":"ACDIMA Biocenter","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Darnitsa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Darnitsa \/ ACDIMA Biocenter","highestDevelopmentStatusID":"6","companyTruncated":"Darnitsa \/ ACDIMA Biocenter"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Canadian Cancer Society | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of British Columbia \/ Canadian Cancer Society | Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"University of British Columbia \/ Canadian Cancer Society | Pfizer Inc"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montreal Heart Institute \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Wagner Macula & Retina Center","sponsor":"Oxurion","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Wagner Macula & Retina Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wagner Macula & Retina Center \/ Oxurion","highestDevelopmentStatusID":"8","companyTruncated":"Wagner Macula & Retina Center \/ Oxurion"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Washington University School of Medicine \/ Pfizer Inc"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Baker Heart and Diabetes Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Baker Heart and Diabetes Institute","highestDevelopmentStatusID":"11","companyTruncated":"Bayside Health \/ Baker Heart and Diabetes Institute"},{"orgOrder":0,"company":"M.p. van den Berg, MD, PhD, professor in Cardiology","sponsor":"University Medical Center Groningen | The Interuniversity Cardiology Institute of the Netherlands | ZonMw | Netherlands: CVON, CardioVascular Research Netherlands","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eplerenone","moa":"Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"M.p. van den Berg, MD, PhD, professor in Cardiology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"M.p. van den Berg, MD, PhD, professor in Cardiology \/ University Medical Center Groningen | The Interuniversity Cardiology Institute of the Netherlands | ZonMw | Netherlands: CVON, CardioVascular Research Netherlands","highestDevelopmentStatusID":"10","companyTruncated":"M.p. van den Berg, MD, PhD, professor in Cardiology \/ University Medical Center Groningen | The Interuniversity Cardiology Institute of the Netherlands | ZonMw | Netherlands: CVON, CardioVascular Research Netherlands"}]

Find Clinical Drug Pipeline Developments & Deals for Eplerenone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Darnitsa

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Darnitsa

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 23, 2022

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : ACDIMA Biocenter

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          NHS National Waiting Times Centre Board

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          NHS National Waiting Times Centre Board

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myocardial Infarction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 20, 2022

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : British Heart Foundation | Abbott Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Wagner Macula & Retina Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Wagner Macula & Retina Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vitreomacular Traction.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 09, 2020

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Oxurion

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Biolab Sanus Farmaceutica

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Biolab Sanus Farmaceutica

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 06, 2016

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Biolab Sanus Farmaceutica

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Biolab Sanus Farmaceutica

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 18, 2015

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Bayside Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Bayside Health

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Aortic Aneurysm, Abdominal.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 26, 2015

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Baker Heart and Diabetes Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Tetralogy of Fallot.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 29, 2013

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          M.p. van den Berg, MD, PhD, professor in Cardiology

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          M.p. van den Berg, MD, PhD, professor in Cardiology

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase III

                          Sponsor : University Medical Center Groningen | The Interuniversity Cardiology Institute of the Netherlands | ZonMw | Netherlands: CVON, CardioVascular Research Netherlands

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cardiomyopathies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 20, 2013

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : University Medical Center Groningen | The Interuniversity Cardiology Institute of the Netherlands | ZonMw | Netherlands: CVON, CardioVascular Research Netherlands

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University of British Columbia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of British Columbia

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 17, 2012

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Canadian Cancer Society | Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Montreal Heart Institute

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Montreal Heart Institute

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Eplerenone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 26, 2012

                          Lead Product(s) : Eplerenone

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank